Reuters logo
BRIEF-Zynerba Pharmaceuticals announces positive top line results in ZYN002 open label Phase 2 FAB-C study
September 28, 2017 / 10:52 AM / in 19 days

BRIEF-Zynerba Pharmaceuticals announces positive top line results in ZYN002 open label Phase 2 FAB-C study

Sept 28 (Reuters) - Zynerba Pharmaceuticals Inc

* Zynerba Pharmaceuticals announces positive top line results in ZYN002 open label Phase 2 FAB-C study in children with Fragile X syndrome

* Zynerba Pharmaceuticals Inc - ‍ZYN002 successfully met primary endpoint and showed clinically meaningful improvements​

* Zynerba Pharmaceuticals Inc - ‍ZYN002 successfully met primary endpoint and showed clinically meaningful improvements​

* Zynerba Pharmaceuticals Inc - ‍study successfully met its primary endpoint,​

* Zynerba Pharmaceuticals Inc says ‍ZYN002 was well tolerated in Fragile X patients​

* Zynerba Pharmaceuticals Inc - ‍zynerba anticipates that it will meet with U.S. Food and Drug Administration in first half of 2018​

* Zynerba Pharmaceuticals - ‍two patients discontinued due to worsening of pre-existing eczema, four other patients experienced an adverse event in trial​

* Zynerba Pharmaceuticals Inc - anticipates ‍moving into pivotal Phase 2/3 program in pediatric and adolescent patients with FXS in 2018​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below